Publications by authors named "Jinyong Hwang"
Introduction: There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction.
Methods And Analysis: The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection fraction >40%) who have been continuing β-blocker therapy for ≥1 year after AMI.
Article Synopsis
- * Results showed that during the first week, STEMI patients had a significantly higher mortality rate (4.62%) compared to NSTEMI patients (1.79%), but this trend reversed after the second week for men and the tenth week for women.
- * The research highlights the need for further studies to develop advanced risk prediction models based on time-point mortality outcomes, as different baseline variables influenced mortality rates over time.
Optimal timing of revascularization for patients who presented with non-ST segment elevation myocardial infarction (NSTEMI) and severe left ventricular (LV) dysfunction is unclear. A total of 386 NSTEMI patients with severe LV dysfunction from the nationwide, multicenter, and prospective Korea Acute Myocardial Infarction Registry V (KAMIR-V) were enrolled. Severe LV dysfunction was defined as LV ejection fraction ≤ 35%.
View Article and Find Full Text PDF: Self-recognition of recurrent myocardial infarction (re-MI) may be essential for reducing prehospital time contrast to awareness of re-MI symptoms. However, data on the current status and clinical impact of self-recognition of re-MI are limited in the contemporary period. Thus, this study aimed to increase this body of knowledge.
View Article and Find Full Text PDFStatin is crucial for acute myocardial infarction (AMI) patients. However, the risk of new-onset diabetes mellitus (NODM) associated with statin is a concern. This study aimed to determine the incremental diabetogenic effects of statins according to their intensity and dose in AMI patients undergoing percutaneous coronary intervention (PCI).
View Article and Find Full Text PDFObjective: The long-term clinical effect of arterial stiffness in high-risk disease entities remains unclear. The prognostic implications of brachial-ankle pulse wave velocity (baPWV) were assessed using a real-world registry that included patients who underwent percutaneous coronary intervention (PCI).
Methods: Arterial stiffness was measured using baPWV before discharge.
Article Synopsis
- In a study of heart patients getting a special procedure called PCI, researchers looked at how two drugs, colchicine and aspirin, affected inflammation and blood clotting.
- They found that patients taking colchicine had lower levels of inflammation compared to those taking aspirin after one month.
- However, both groups showed similar levels of blood clotting, meaning colchicine helped with inflammation without making blood clots more likely.
Imaging modalities for percutaneous coronary intervention (PCI), such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT), have increased in the current PCI era. However, their clinical benefits in acute myocardial infarction (AMI) have not been fully elucidated. This study investigated the long-term outcomes of image-guided PCI in patients with AMI using data from the Korean Acute Myocardial Infarction Registry.
View Article and Find Full Text PDFBackground And Aims: Platelet-fibrin clot strength (PFCS) is linked to major adverse cardiovascular event (MACE) risk. However, the association between PFCS and platelet reactivity and their prognostic implication remains uncertain in patients undergoing percutaneous coronary intervention (PCI).
Methods: In PCI-treated patients (n = 2512) from registry data from January 2010 to November 2018 in South Korea, PFCS using thromboelastography and platelet reactivity using VerifyNow were measured.
Article Synopsis
- The study evaluated the effectiveness and tolerability of combining irbesartan (IRB) and amlodipine (AML) in treating essential hypertension when IRB alone was insufficient.
- Two phase III clinical trials in Korea involved 428 patients and compared combinations of IRB/AML to placebo over 8 weeks, focusing on changes in mean sitting systolic blood pressure (MSSBP).
- Results showed significant reductions in MSSBP in the combination groups compared to monotherapy, with adverse events occurring in a small percentage of participants, indicating the combined therapy was both effective and tolerable.
Article Synopsis
- Current guidelines suggest complete revascularization (CR) for stable patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), but the best timing for the procedure is still unclear.
- The OPTION-STEMI trial investigates whether immediate CR during a primary angioplasty is as effective as in-hospital staged CR, using fractional flow reserve (FFR) assessments for certain lesions.
- The trial enrolled patients with significant non-infarct-related artery lesions, aiming to measure outcomes like death and myocardial infarction one year post-randomization, with results expected in mid-2025.
Introduction And Objectives: There are no clinical data on the efficacy of intravascular imaging-guided percutaneous coronary intervention (PCI) compared with angiography-guided PCI in patients with acute myocardial infarction (AMI) and cardiogenic shock. The current study sought to evaluate the impact of intravascular imaging-guided PCI in patients with AMI and cardiogenic shock.
Methods: Among a total of 28 732 patients from the nationwide pooled registry of KAMIR-NIH (November, 2011 to December, 2015) and KAMIR-V (January, 2016 to June, 2020), we selected a total of 1833 patients (6.
Background: Limited data exist regarding the prognostic implications of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with non-ST-elevation myocardial infarction (NSTEMI) who undergo percutaneous coronary intervention (PCI).
Methods and results: Of 13,104 patients in the nationwide Korea Acute Myocardial Infarction Registry-National Institutes of Health, 3,083 patients with NSTEMI who underwent PCI were included in the present study. The primary endpoint was major adverse cardiovascular events (MACE) at 3 years, a composite of all-cause death, recurrent myocardial infarction, unplanned repeat revascularization, and admission for heart failure.
Background: Cilostazol has a vasodilatory function that may be beneficial for patients with vasospastic angina (VSA). We conducted a randomized, open-label, controlled trial to compare the efficacy and safety of long-acting cilostazol and isosorbide mononitrate (ISMN) for VSA.
Methods: The study included patients with confirmed VSA between September 2019 and May 2021.
Background: During fractional flow reserve (FFR) measurements, distal coronary pressure (Pd) can be influenced by hydrostatic pressure changes resulting from the height difference (HD) between the coronary ostium and the location of the distal pressure sensor.
Aims: We investigated the effect of aortocoronary HD on the FFR measurements in each coronary artery.
Methods: In this retrospective cohort study, we analyzed 257 patients who underwent FFR measurements and coronary computed tomography (CCTA) within a year.
Article Synopsis
- * In a trial with 374 hypertensive patients, those receiving the triple therapy saw a significant decrease in mean sitting systolic blood pressure after 8 weeks compared to the dual therapy group.
- * Results indicated that the triple therapy led to higher rates of achieving target blood pressure and a lower occurrence of adverse events, especially among women and patients aged 65 and older.
Background: Acute myocardial infarction (AMI) is one of the leading causes of death worldwide, and approximately half of AMI-related deaths occur before the affected individual reaches the hospital. The present study aimed to identify and validate genetic variants associated with AMI and their role as prognostic markers.
Materials And Methods: We conducted a replication study of 29 previously identified novel loci containing 85 genetic variants associated with early-onset AMI using a new independent set of 2,920 Koreans [88 patients with early- and 1,085 patients with late-onset AMI, who underwent percutaneous coronary intervention (PCI), and 1,747 healthy controls].
Background Data on the incidence, relevant patient factors, and clinical outcomes of the misdiagnosis of ST-segment-elevation myocardial infarction (STEMI) in the modern era of percutaneous coronary intervention are limited. Methods and Results Data from KAMIR (Korea Acute Myocardial Infarction Registry) between November 2011 and June 2020 were analyzed. Out of 28 470 patients with acute myocardial infarction, 11 796 were eventually diagnosed with STEMI following a coronary angiogram.
View Article and Find Full Text PDFBackground: The prognostic utility of follow-up transthoracic echocardiography (FU-TTE) in patients with hypertrophic cardiomyopathy (HCM) is unclear, specifically in terms of whether changes in echocardiographic parameters in routine FU-TTE parameters are associated with cardiovascular outcomes.
Methods: From 2010 to 2017, 162 patients with HCM were retrospectively enrolled in this study. Using echocardiography, HCM was diagnosed based on morphological criteria.
Background/aims: Bleeding events after percutaneous coronary intervention (PCI) have important prognostic implications. Data on the influence of an abnormal ankle-brachial index (ABI) on both ischemic and bleeding events in patients undergoing PCI are limited.
Methods: We included patients who underwent PCI with available ABI data (abnormal ABI, ≤ 0.
There has been a concern that angiotensin receptor blockers (ARB) may increase myocardial infarction (MI) in hypertensive patients compared with other classes of anti-hypertensive drugs. Angiotensin-converting enzyme inhibitor (ACEI) is recommended as a first-line inhibitor of renin-angiotensin system (RASI) in patients with acute MI (AMI), but ARB is also frequently used to control blood pressure. This study investigated the association of ARB vs.
View Article and Find Full Text PDFAims: Atherothrombotic events are influenced by systemic hypercoagulability and fibrinolytic activity. The present study evaluated thrombogenicity indices and their prognostic implications according to disease acuity.
Methods And Results: From the consecutive patients undergoing percutaneous coronary intervention (PCI), those with thrombogenicity indices (n = 2705) were grouped according to disease acuity [acute myocardial infarction (AMI) vs.
Article Synopsis
- High-sensitivity C-reactive protein (hs-CRP) was studied in 4,263 East Asian patients who underwent PCI for either acute myocardial infarction (AMI) or stable disease, to understand its role in inflammation and cardiovascular risk.
- The AMI group showed significantly higher hs-CRP levels both at baseline and one month post-PCI compared to the non-AMI group, with a high hs-CRP score linked to greater risk of adverse cardiovascular events primarily in AMI patients.
- While AMI patients had higher inflammation levels immediately and in the long term, both AMI and non-AMI patients exhibited similar risks associated with hs-CRP during the long-term phase, indicating a consistent prognostic value
Background: Clinical evidence raises the issues regarding the high risk of adverse events and serious bleeding in East Asian patients receiving standard-dose ticagrelor treatment. We sought to evaluate the association between adverse events and their associations with premature discontinuation of dual antiplatelet therapy (DAPT).
Methods: We enrolled East Asian patients presented with acute coronary syndrome who took DAPT with 90-mg ticagrelor ( = 270) or 75-mg clopidogrel ( = 674).
Background: East Asian population has a low level of inflammation compared with Western population. The prognostic implication of residual inflammatory risk (RIR) remains uncertain in East Asians.
Objectives: This study sought to provide an analysis to estimate early-determined RIR and its association with clinical outcomes in East Asian patients with coronary artery disease (CAD).